AtriCure announced the successful first-in-human AFib treatments using its novel dual-energy surgical cardiac ablation platform.
Zacks Investment Research on MSN
Boston Scientific sustains momentum in the PFA market: What's next?
Atrial fibrillation (AF or AFib) is one of the most common abnormal heart rhythms, affecting nearly 38 million people worldwide — a figure projected to nearly triple by 2030. Boston Scientific BSX ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback